Self-assembled nanoparticles from folate-decorated maleilated pullulan-doxorubicin conjugate for improved drug delivery to cancer cells

Polymer International

Volumn 62, Issue 2, 2013, Pages 165-171

  Li, Fei ^a   Zhang, Haitao ^a,b   Gu, Chunhu ^c   Fan, Li ^a   Qiao, Youbei ^a   Tao, Yangchun ^a   Cheng, Chong ^a   Wu, Hong ^a   Yi, Jun ^c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b NORTHWESTERN POLYTECHNICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Drug targeting; Multidrug resistance; Nanoparticle; Pullulan doxorubicin conjugates

Indexed keywords

ANTITUMOR EFFECT; AVERAGE DIAMETER; CANCER CELLS; CELL VIABILITY; CELLULAR UPTAKE; DOXORUBICIN; DOXORUBICIN CONJUGATES; DRUG-TARGETING; IN-VITRO TESTS; MULTIDRUG RESISTANCE; PH-DEPENDENT; PULLULAN-DOXORUBICIN CONJUGATES; PYRROLIDINEDITHIOCARBAMATE; RECEPTOR-MEDIATED ENDOCYTOSIS; SELF ASSEMBLED NANOPARTICLES; SIDE EFFECT; SPHERICAL GEOMETRIES; SUSTAINED RELEASE;

CELLS; CYTOLOGY; DRUG DELIVERY; DRUG INTERACTIONS; DRUG PRODUCTS; MOLECULAR BIOLOGY;

NANOPARTICLES;

EID: 84872676428     PISSN: 09598103     EISSN: 10970126     Source Type: Journal    
DOI: 10.1002/pi.4272     Document Type: Article

References (33)

1. Al-Shabanah OA, El-Kashef HA, Badary OA, Al-Bekairi AM and Elmazar MMA, Pharmacol Res 41: 31-37 (2000).
2. Petit T, Bull Cancer 91(Suppl 3): 159-165 (2004).
3. Kim SY, Shin IG and Lee YM, Biomaterials 20: 1033-1042 (1999).
4. Kim D, Lee ES, Oh KT, Gao ZG and Bae YH, Small 4: 2043-2050 (2008).
5. Chun L and Sidney W, Adv Drug Deliv Rev 60: 886-898 (2008).
6. Gabizon AA, Cancer Res 52: 891-896 (1992).
7. Sutton D, Nasongkla N, Blanco E and Gao J, Pharmacol Res 24: 1029-1046 (2007).
8. Oh JK, Drumright R, Siegwart DJ and Matyjaszewski K, Prog Polym Sci 33: 448-477 (2008).
9. Kawaguchi H, Prog Polym Sci 25: 1171-1210 (2000).
10. Kopeček J, Kopečková P, Minko T and Lu ZR, Eur J Pharm Biopharm 50: 61-81 (2000).
11. Chytil P, Etrych T, Konak C, Sirova M, Mrkvan T, Rihova B, et al, J Control Release 115: 26-36 (2006).
12. Greenwald RB, Choe YH, McGuire J and Conover CD, Adv Drug Deliv Rev 55: 217-250 (2003).
13. Azzam T, Eliyahu H, Shapira L, Linial M, Barenholz Y and Domb AJ, J Med Chem 45: 1817-1824 (2002).
14. Rapoport N, Marin A, Luo Y, Prestwich GD and Muniruzzaman M, J Pharm Sci 91: 157-170 (2002).
15. Hovgaard L and Brondsted H, Crit Rev Ther Drug Carrier Syst 13: 185-223 (1996).
16. Sinha VR and Kumria R, Int J Pharm 224: 19-38 (2001).
17. Marcucci F and Lefoulon F, Drug Discov Today 9: 219-228 (2004).
18. Reddy JA and Low PS, J Control Release 64: 27-37 (2000).
19. Guo W, Lee T, Sudimack JJ and Lee RJ, J Liposome Res 10: 179-195 (2000).
20. Lee RJ and Low PS, Biochim Biophys Acta 1233: 134-144 (1995).
21. Yoo HS and Park TG, J Control Release 100: 247-256 (2004).
22. Yoo HS and Park TG, J Control Release 96: 273-283 (2004).
23. Sunamoto J, Ushio K and Lai DT, J Bioact Compat Polym 21: 603-617 (2006).
24. Hidaka M, Kanematsu T, Ushio K and Sunamoto J, J Bioact Compat Polym 21: 591-602 (2006).
25. Lu DX, Wen XT, Liang J, Zhang XD, Gu ZW and Fan YJ, J Biomed Mater Res B 89: 177-183 (2009).
26. Nogusa H, Yamamoto K, Yano T, Kajiki M, Hamana H and Okuno S, Biol Pharm Bull 23: 621-626 (2000).
27. Nogusa H, Yano T, Okuno S, Hamana H and Inoue K, Chem Pharm Bull 43: 1931-1936 (1995).
28. Zhang HT, Li F, Yi J, Gu CH, Fan L, Qiao YB, et al, Eur J Pharm Sci 42: 517-526 (2011).
29. Fan L, Li F, Zhang HT, Wang YK, Cheng C, Li XY, et al, Biomaterials 31: 5634-5642 (2010).
30. van Wijngaarden J, van Beek E, van Rossum G, van der Bent C, Hoekman K, van der Pluijm G, et al, Eur J Cancer 43: 433-442 (2007).
31. Turdi S, Xu P, Li Q, Shen Y, Kerram P and Ren J, Toxicol Lett 178: 197-201 (2008).
32. Kataoka K, Matsumoto T, Yokoyama M, Okano T, Sakurai Y, Fukushima S, et al, J Control Release 64: 143-153 (2000).
33. Sutton D, Nasongkla N, Blanco E and Gao JM, Pharmacol Res 24: 1029-1046 (2007).